Ethopropazine

CHEMBL1206 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
312.5 g/mol
LogP
4.8
Phase
4

This phenothiazine medication blocks certain receptors in the nervous system and has anticholinergic properties that help relieve muscle stiffness and tremor in Parkinson's disease. It also has some antihistamine activity.

Khối lượng phân tử

312,5000 g/mol

LogP

4,80

TPSA

31,80 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21

InChI

InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3

Molecular Formula

C19H24N2S

HBD / HBA

- / 3

Liên kết có thể quay

5

Nguyên tử nặng

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This phenothiazine medication blocks certain receptors in the nervous system and has anticholinergic properties that help relieve muscle stiffness and tremor in Parkinson's disease. It also has some antihistamine activity.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Ethopropazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1206. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3290. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.